Fabry Disease - Market Insights, Epidemiology and Market Forecast - 2025

  • ID: 4401846
  • Drug Pipelines
  • 70 Pages
  • DelveInsight
1 of 4
Covers the Therapeutics Market Revenue, Treatment Practice/Algorithm and Forecasted Market Size of Anderson-Fabry Disease from 2017 to 2025 Segmented by Seven Major Markets

FEATURED COMPANIES

  • Amicus Therapeutics, Inc.
  • Protalix Biotherapeutics
  • Sanofi-Aventis
  • Shire Plc.
  • MORE
Anderson-Fabry Disease - Market Insights, Epidemiology & Market Forecast-2025 provides an overview of the Anderson-Fabry Disease, epidemiology and market trend of the Anderson-Fabry Disease for the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The report covers the therapeutics market revenue, treatment practice/algorithm and forecasted market size of Anderson-Fabry Disease from 2017 to 2025 segmented by seven major markets. In addition, the report also includes the forecasted epidemiology of Anderson-Fabry Disease till 2025. It also covers market drivers, market barriers and unmet medical need.

Our report provides the subtype specific prevalent population i.e. Classic Fabry Disease and Later-onset Fabry disease. According to research, the prevalent population of Anderson-Fabry Disease is expected to reach up to XXX cases by the end of 2025 at a CAGR of 1.3% from 2015-2025. High prevalent cases were observed in United States as compared to EU5 and Japan.

Fabry Disease market has experienced a continuous growth due to approved therapies such as Fabrazyme (agalsidase beta) from Sanofi Genzyme and Replagal (ERT based therapy) from Shire. Sanofi Genzyme is currently dominating the Fabry market with its lead product Fabrazyme.

United States contributes the major share of Fabry disease market as compared to EU5 countries and Japan. The therapeutic market of Fabry disease in 7MM is expected to reach USD 2.1 Billion in 2025 at the CAGR of XX% from 2015-2025.

Key Coverage and Benefits:
  • The report will help in developing business strategies by understanding the trends shaping and driving the global Anderson-Fabry Disease market.
  • The report provides detailed historical and forecasted epidemiological data of Anderson-Fabry Disease in the 7MM i.e., United States, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan from 2015-2025.
  • Organize sales and marketing efforts by identifying the best opportunities for Anderson-Fabry Disease in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.
  • To understand the future market competition in the global Anderson-Fabry Disease and insightful review of the key market drivers and barriers.
  • To understand the regulatory scenario in major markets.
  • The report covers the detailed historical and forecasted Anderson-Fabry Disease market covering the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
Note: Please allow up to 24 hours for delivery after payment has been made.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Amicus Therapeutics, Inc.
  • Protalix Biotherapeutics
  • Sanofi-Aventis
  • Shire Plc.
  • MORE
1. Report Introduction
1.1.1. Anderson-Fabry Disease Market Overview at a Glance
1.1.2. Market Share Distribution of Anderson-Fabry Disease in 2016
1.1.3. Market Share Distribution of Anderson-Fabry Disease in 2025
1.1.4. Total Market by Region of Anderson-Fabry Disease (2016 & 2025)

2. Disease Background and Overview

3. Introduction
3.1.1. Timeline for Anderson-Fabry Disease
3.1.2. Classification
3.1.3. Signs and Symptoms
3.1.4. Etiology
3.1.5. Inheritance Pattern
3.1.6. Pathophysiology
3.1.7. Diagnosis
3.1.8. European Fabry Working Group (EFWG): Diagnostic criteria
3.1.9. Challenges in Diagnosis
3.1.10. Expert Opinions Regarding Diagnosis of Fabry Disease

4. Epidemiology and Patient Population
4.1.1. Prevalent Population of Anderson-Fabry Disease in 7MM
4.1.2. Prevalent Population of Anderson-Fabry Disease in 7MM - By Region
4.1.3. Prevalent Population of Anderson-Fabry Disease in 7MM - Distribution (2016)
4.1.4. Prevalent Population of Anderson-Fabry Disease in 7MM - Distribution (2025)
4.1.5. United States
4.1.6. Prevalent Population of Anderson-Fabry Disease
4.1.7. Sex-Specific Prevalent Population of Anderson-Fabry Disease
4.1.8. Sub-type Specific Prevalent Population of Anderson-Fabry Disease
4.1.9. EU5 countries
4.1.10. Germany
4.1.11. Prevalent Population of Anderson-Fabry Disease
4.1.12. Sex-Specific Prevalent Population of Anderson-Fabry Disease
4.1.13. Sub-type - Specific Prevalent Population of Anderson-Fabry Disease
4.1.14. France
4.1.15. Prevalent Population of Anderson-Fabry Disease
4.1.16. Sex-Specific Prevalent Population of Anderson-Fabry Disease
4.1.17. Sub-type Specific Prevalent Population of Anderson-Fabry Disease
4.1.18. United Kingdom
4.1.19. Prevalent Population of Anderson-Fabry Disease
4.1.20. Sex-Specific Prevalent Population of Anderson-Fabry Disease
4.1.21. Sub-type Specific Prevalent Population of Anderson-Fabry Disease
4.1.22. Spain
4.1.23. Prevalent Population of Anderson-Fabry Disease
4.1.24. Sex-Specific Prevalent Population of Anderson-Fabry Disease
4.1.25. Sub-type Specific Prevalent Population of Anderson-Fabry Disease
4.1.26. Italy
4.1.27. Prevalent Population of Anderson-Fabry Disease
4.1.28. Sex-Specific Prevalent Population of Anderson-Fabry Disease
4.1.29. Sub-type Specific Prevalent Population of Anderson-Fabry Disease
4.1.30. Japan
4.1.31. Prevalent Population of Anderson-Fabry Disease
4.1.32. Sex-Specific Prevalent Population of Anderson-Fabry Disease
4.1.33. Sub-type Specific Prevalent Population of Anderson-Fabry Disease

5. Treatment Practices

6. Treatment Goals

7. Treatment Algorithm
7.1.1. Guidelines for management of Fabry Disease
7.1.2. Croatian Society: Recommendation for the treatment of Fabry Disease
7.1.3. Expert Opinions Regarding the Treatment of Fabry Disease

8. Marketed Drugs List

9. Marketed Drugs
9.1.1. Galafold: Amicus Therapeutics, Inc.
9.1.2. Drug Description
9.1.3. Mechanism of Action
9.1.4. Regulatory Milestones
9.1.5. Advantages & Disadvantages
9.1.6. Safety and Efficacy
9.1.7. Product Profile
9.1.8. Side-Effects
9.1.9. Drug Sales
9.1.10. Replagal: Shire Plc.
9.1.11. Drug Description
9.1.12. Mechanism of Action
9.1.13. Regulatory Milestones
9.1.14. Advantages & Disadvantages
9.1.15. Safety and Efficacy
9.1.16. Product Profile
9.1.17. Side-Effects
9.1.18. Drug Sales
9.1.19. Fabrazyme: Sanofi-Aventis
9.1.20. Drug Description
9.1.21. Mechanism of Action
9.1.22. Regulatory Milestones
9.1.23. Advantages & Disadvantages
9.1.24. Safety and Efficacy
9.1.25. Product Profile
9.1.26. Side-Effects
9.1.27. Drug Sales
9.1.28. Emerging Therapies
9.1.29. Phase-III Drugs Analysis
9.1.30. Expert commentary for Key Emerging Drugs
9.1.31. Phase III and Filed Drugs
9.1.32. Migalastat: Amicus Therapeutics Inc.
9.1.33. Regulatory Milestones
9.1.34. Other development activities
9.1.35. Clinical Development
9.1.36. Clinical Trials Information
9.1.37. Safety and Efficacy
9.1.38. Advantages and Disadvantages
9.1.39. Product Profile
9.1.40. PRX-102: Protalix Biotherapeutics
9.1.41. Regulatory Milestones
9.1.42. Other development activities
9.1.43. Clinical Development
9.1.44. Ongoing Trials Information
9.1.45. Safety and Efficacy
9.1.46. Advantages and Disadvantages
9.1.47. Product Profile
9.1.48. Phase II Drugs
9.1.49. GZ/SAR402671: Sanofi-Aventis
9.1.50. Regulatory Milestones
9.1.51. Other development activities
9.1.52. Clinical Development
9.1.53. Clinical Trials Information
9.1.54. Product Profile
9.1.55. Current Unmet Need

10. Anderson-Fabry Disease: Market Analysis
10.1.1. Market Outlook: Global
10.1.2. Market size of Anderson-Fabry Disease - Global (2015-2025)
10.1.3. Market Outlook: 7Major Markets
10.1.4. Market size of Anderson-Fabry Disease in 7MM (2016)
10.1.5. Market size of Anderson-Fabry Disease in 7MM (2025)
10.1.6. Market size of Anderson-Fabry Disease in 7MM

11. Market Outlook
11.1.1. US Market size
11.1.2. Market size by Drug Administration
11.1.3. Anderson-Fabry Disease: EU5

12. Market Outlook
12.1.1. Germany Market size
12.1.2. Market size by Drug Administration
12.1.3. France Market size
12.1.4. Market size by Drug Administration
12.1.5. United Kingdom Market size
12.1.6. Market size by Drug Administration
12.1.7. Spain Market size
12.1.8. Market size by Drug Administration
12.1.9. Italy Market size
12.1.10. Market size by Drug Administration

13. Anderson-Fabry Disease: Japan Market Outlook
13.1.1. Japan Market size
13.1.2. Market size by Drug Administration

14. Market Drivers

15. Market Barriers

16. Appendix

17. Report Methodology

18. Consulting Services

19. Disclaimer

20. About

List of Tables
Table 1: Pathophysiologic findings in Anderson-Fabry Disease
Table 2: Proposed assessments for Anderson-Fabry Disease
Table 3: Clinical evaluation and monitoring of adult patients with Fabry Disease
Table 4: Clinical evaluation and monitoring of pediatric patients with Fabry Disease
Table 5: Diagnostic criteria of European Fabry Working Group (EFWG)
Table 6: Fabry disease: Common misdiagnoses
Table 7: Prevalent Population of Anderson-Fabry Disease in 7MM (2015-2025)
Table 8: Prevalent Population of Anderson-Fabry Disease in 7MM (2015-2025)
Table 9: Prevalent Population of Anderson-Fabry Disease in United States (2015-2025)
Table 10: Sex-Specific Prevalent Population of Anderson-Fabry Disease in United States (2015-2025)
Table 11: Sub-type Specific Prevalent Population of Anderson-Fabry Disease in United States (2016)
Table 12: Prevalent Population of Anderson-Fabry Disease in Germany (2015-2025)
Table 13: Sex-Specific Prevalent Population of Anderson-Fabry Disease in Germany (2015-2025)
Table 14: Sub-type Specific Prevalent Population of Anderson-Fabry Disease in Germany (2016)
Table 15: Prevalent Population of Anderson-Fabry Disease in France (2015-2025)
Table 16: Sex-Specific Prevalent Population of Anderson-Fabry Disease in France (2015-2025)
Table 17: Sub-type Specific Prevalent Population of Anderson-Fabry Disease in France (2016)
Table 18: Prevalent Population of Anderson-Fabry Disease in United Kingdom (2015-2025)
Table 19: Sex-Specific Prevalent Population of Anderson-Fabry Disease United Kingdom (2015-2025)
Table 20: Sub-type Specific Prevalent Population of Anderson-Fabry Disease in United Kingdom (2016)
Table 21: Prevalent Population of Anderson-Fabry Disease in Spain (2015-2025)
Table 22: Sex-Specific Prevalent Population of Anderson-Fabry Disease in Spain (2015-2025)
Table 23: Sub-type Specific Prevalent Population of Anderson-Fabry Disease in Spain (2016)
Table 24: Prevalent Population of Anderson-Fabry Disease in Italy (2015-2025)
Table 25: Sex-Specific Prevalent Population of Anderson-Fabry Disease in Italy (2015-2025)
Table 26: Sub-type Specific Prevalent Population of Anderson-Fabry Disease in Italy (2016)
Table 27: Prevalent Population of Anderson-Fabry Disease in Japan (2015-2025)
Table 28: Sex-Specific Prevalent Population of Anderson-Fabry Disease in Japan (2015-2025)
Table 29: Sub-type Specific Prevalent Population of Anderson-Fabry Disease in Japan (2016)
Table 30: Treatment goals for Fabry Disease patients associated with other conditions
Table 31: Effect of enzyme replacement therapy on signs and Symptoms of Fabry Disease
Table 32: Enzyme Replacement Therapy
Table 33: Recommended analgesic drugs for supportive treatment of Chronic neuropathic pain in Fabry Disease
Table 34: Recommended analgesic drugs for supportive treatment of acute pain in Fabry Disease
Table 35: Current guidelines for instituting enzyme replacement therapy in Fabry Disease patients
Table 36: Adjunctive therapies and preventive measures in Fabry Disease patients for common Fabry related morbidities
Table 37: Implications for Recommendations
Table 38: List of Marketed Drugs for Disease
Table 39: Comparison of Phase-III drugs under development
Table 40: Phase-III drugs: Safety and Efficacy
Table 41: Expert commentary for Key Emerging Drugs
Table 42: Migalastat, Clinical Trial Description, 2017
Table 43: PRX-102, Clinical Trial Description, 2017
Table 44: GZ/SAR402671, Clinical Trial Description, 2017
Table 45: Global Market Size of Anderson-Fabry Disease in USD Million (2015-2025)
Table 46: 7 Major Market Size of Anderson-Fabry Disease in USD Million (2015-2025)
Table 47: Market Size of Anderson-Fabry Disease in United States, USD Millions (2015-2025)
Table 48: Market Size by Drug Administration of Anderson-Fabry Disease in United States, USD Millions (2015-2025)
Table 49: Market Size of Anderson-Fabry Disease in Germany , USD Million (2015-2025)
Table 50: Market Size by Drug Administration of Anderson-Fabry Disease in Germany, USD Millions (2015-2025)
Table 51: Market Size of Anderson-Fabry Disease in France, USD Million (2015-2025)
Table 52: Market Size by Drug Administration of Anderson-Fabry Disease in France, USD Millions (2015-2025)
Table 53: Market Size of Anderson-Fabry Disease in United Kingdom, USD Million (2015-2025)
Table 54: Market Size by Drug Administration of Anderson-Fabry Disease in United Kingdom, USD Millions (2015-2025)
Table 55: Market Size of Anderson-Fabry Disease in Spain , USD Million (2015-2025)
Table 56: Market Size by Drug Administration of Anderson-Fabry Disease in Spain, USD Millions (2015-2025)
Table 57: Market Size of Anderson-Fabry Disease in Italy, USD Million (2015-2025)
Table 58: Market Size by Drug Administration of Anderson-Fabry Disease in Italy, USD Millions (2015-2025)
Table 59: Market Size of Anderson-Fabry Disease in Japan , USD Million (2015-2025)
Table 60: Market Size by Drug Administration of Anderson-Fabry Disease in Japan, USD Millions (2015-2025)

List of Figures
Figure 1: Timeline for Anderson-Fabry Disease
Figure 2: Characteristics of Type 1 classic and Type 2 later-onset Anderson-Fabry Disease
Figure 3: Symptoms of Anderson-Fabry Disease in Adults, Childhood and Adolescence
Figure 4: Inheritance Pattern of Anderson-Fabry Disease
Figure 5: Genetic and molecular basis of Anderson-Fabry Disease
Figure 6: Diagnosis Algorithm for Anderson-Fabry Disease
Figure 7: Prevalent Population of Anderson-Fabry Disease in 7MM (2015-2025)
Figure 8: Prevalent Population of Anderson-Fabry Disease in 7MM (2015-2025)
Figure 9: Prevalent Population of Anderson-Fabry Disease in United States (2015-2025)
Figure 10: Sex-Specific Prevalent Population of Anderson-Fabry Disease in United States (2015-2025)
Figure 11: Sub-type Specific Prevalent Population of Anderson-Fabry Disease in United States (2016)
Figure 12: Prevalent Population of Anderson-Fabry Disease in Germany (2015-2025)
Figure 13: Sex-Specific Prevalent Population of Anderson-Fabry Disease in Germany (2015-2025)
Figure 14: Sub-type Specific Prevalent Population of Anderson-Fabry Disease in Germany (2016)
Figure 15: Prevalent Population of Anderson-Fabry Disease in France (2015-2025)
Figure 16: Sex-Specific Prevalent Population of Anderson-Fabry Disease in France (2015-2025)
Figure 17: Sub-type Specific Prevalent Population of Anderson-Fabry Disease in France (2016)
Figure 18: Prevalent Population of Anderson-Fabry Disease in United Kingdom (2015-2025)
Figure 19: Sex-Specific Prevalent Population of Anderson-Fabry Disease in United Kingdom (2015-2025)
Figure 20: Sub-type Specific Prevalent Population of Anderson-Fabry Disease in United Kingdom (2016)
Figure 21: Prevalent Population of Anderson-Fabry Disease in Spain (2015-2025)
Figure 22: Sex-Specific Prevalent Population of Anderson-Fabry Disease in Spain (2015-2025)
Figure 23: Sub-type Specific Prevalent Population of Anderson-Fabry Disease in Spain (2016)
Figure 24: Prevalent Population of Anderson-Fabry Disease in Italy (2015-2025)
Figure 25: Sex-Specific Prevalent Population of Anderson-Fabry Disease in Italy (2015-2025)
Figure 26: Sub-type Specific Prevalent Population of Anderson-Fabry Disease in Italy (2016)
Figure 27: Prevalent Population of Anderson-Fabry Disease in Japan (2015-2025)
Figure 28: Sex-Specific Prevalent Population of Anderson-Fabry Disease in Japan (2015-2025)
Figure 29: Sub-type Specific Prevalent Population of Anderson-Fabry Disease in Japan (2016)
Figure 30: Treatment Algorithm for Anderson-Fabry Disease
Figure 31: Current Unmet Needs of Anderson-Fabry Disease
Figure 32: Global Market Size of Anderson-Fabry Disease in USD Million (2015-2025)
Figure 33: 7 Major Market Size of Anderson-Fabry Disease in USD Million (2015-2025)
Figure 34: Market Size of Anderson-Fabry Disease in United States, USD Millions (2015-2025)
Figure 35: Market Size by Drug Administration of Anderson-Fabry Disease in United States, USD Millions (2015-2025)
Figure 36: Market Size of Anderson-Fabry Disease in Germany , USD Million (2015-2025)
Figure 37: Market Size by Drug Administration of Anderson-Fabry Disease in Germany, USD Millions (2015-2025)
Figure 38: Market Size of Anderson-Fabry Disease in France, USD Million (2015-2025)
Figure 39: Market Size by Drug Administration of Anderson-Fabry Disease in France, USD Millions (2015-2025)
Figure 40: Market Size of Anderson-Fabry Disease in United Kingdom, USD Million (2015-2025)
Figure 41: Market Size by Drug Administration of Anderson-Fabry Disease in United Kingdom, USD Millions (2015-2025)
Figure 42: Market Size of Anderson-Fabry Disease in Spain, USD Million (2015-2025)
Figure 43: Market Size by Drug Administration of Anderson-Fabry Disease in Spain, USD Millions (2015-2025)
Figure 44: Market Size of Anderson-Fabry Disease in Italy, USD Million (2015-2025)
Figure 45: Market Size by Drug Administration of Anderson-Fabry Disease in Italy, USD Millions (2015-2025)
Figure 46: Market Size of Anderson-Fabry Disease in Japan, USD Million (2015-2025)
Figure 47: Market Size by Drug Administration of Anderson-Fabry Disease in Japan, USD Millions (2015-2025)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Amicus Therapeutics, Inc.
  • Shire Plc.
  • Sanofi-Aventis
  • Protalix Biotherapeutics
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll